NASDAQ Global Select • Healthcare • Biotechnology • US • USD
Cyclerion Therapeutics, Inc. (CYCN) has a consensus analyst rating of Buy, based on 2 analysts covering the stock. Of those, 2 recommend buying, 0 recommend holding, and 0 recommend selling.
No price target data available.
Be the first to know when stocks drop below their intrinsic value.
